Loading news...
Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) shares dropped 1.2% during trading on Monday. The stock traded as low as $1.64 and last traded at $1.67. Approximately 197,840 shares were traded during trading, a decline of 29% from the average daily volume of 280,509 shares. The stock had previously closed at $1.69. Analyst Ratings
MGX Resources Limited (MTGRY) Shareholder/Analyst Call Prepared Remarks Transcript
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has completed its corporate name change to Metagenomi Therapeutics, Inc. to reflect the Company's strategic evolution focused on driving forward the Company's lead program in hemophilia A and other compelling programs and technologies that have the highest probability of near-term success.
Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Earnings and Valuation This table compares Madrigal Pharmaceuticals and
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, MA.
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.
Metagenomi, Inc. (NASDAQ:MGX) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program.
Metagenomi (MGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.45 per share a year ago.
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates
MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from the Company's MGX-001 hemophilia A program.
Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some of its work in developing gene-editing technologies.
Does Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
CNBC's Steve Kovach reports on news regarding the backers of a U.S.-TikTok deal.
Metagenomi (MGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.29 per share a year ago.
Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million in cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended June 30, 2025, and provided business updates.
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors.
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -
Metagenomi (MGX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.19 per share a year ago.
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile